Published in BMC Neurol on August 13, 2012
Parkinsonism in spinocerebellar ataxia. Biomed Res Int (2015) 0.77
Examination of Huntington's disease in a Chinese family. Neural Regen Res (2014) 0.77
The Pathogenic Role of Low Range Repeats in SCA17. PLoS One (2015) 0.75
Spinocerebellar ataxia 17: Inconsistency between phenotype and neuroimage findings. Ann Indian Acad Neurol (2013) 0.75
Cognitive Changes in the Spinocerebellar Ataxias Due to Expanded Polyglutamine Tracts: A Survey of the Literature. Brain Sci (2017) 0.75
Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol (2004) 3.83
SCA17 homozygote showing Huntington's disease-like phenotype. Ann Neurol (2004) 1.72
A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? Hum Mol Genet (1999) 1.69
Trinucleotide repeats in 202 families with ataxia: a small expanded (CAG)n allele at the SCA17 locus. Arch Neurol (2002) 1.26
Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes. Brain (2003) 1.26
Different types of repeat expansion in the TATA-binding protein gene are associated with a new form of inherited ataxia. Eur J Hum Genet (2001) 1.08
SCA17 repeat expansion: mildly expanded CAG/CAA repeat alleles in neurological disorders and the functional implications. Clin Chim Acta (2009) 1.00
Spinocerebellar ataxia type 17: report of a family with reduced penetrance of an unstable Gln49 TBP allele, haplotype analysis supporting a founder effect for unstable alleles and comparative analysis of SCA17 genotypes. BMC Med Genet (2005) 0.96
Spinocerebellar ataxia type 17 associated with an expansion of 42 glutamine residues in TATA-box binding protein gene. J Neurol Neurosurg Psychiatry (2010) 0.96
Structural changes associated with progression of motor deficits in spinocerebellar ataxia 17. Cerebellum (2010) 0.91
Case of spinocerebellar ataxia type 17 (SCA17) associated with only 41 repeats of the TATA-binding protein (TBP) gene. Mov Disord (2007) 0.91
Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models. J Genet (2010) 0.90
Spinocerebellar ataxia type 17: extension of phenotype with putaminal rim hyperintensity on magnetic resonance imaging. Mov Disord (2005) 0.89
The SCA17 phenotype can include features of MSA-C, PSP and cognitive impairment. Parkinsonism Relat Disord (2006) 0.88
Huntington's disease-like and ataxia syndromes: identification of a family with a de novo SCA17/TBP mutation. Parkinsonism Relat Disord (2010) 0.88
Characterization of nigrostriatal dysfunction in spinocerebellar ataxia 17. Mov Disord (2006) 0.80
A small trinucleotide expansion in the TBP gene gives rise to a sporadic case of SCA17 with abnormal putaminal findings on MRI. Intern Med (2008) 0.79
Putamen dopamine transporter and glucose metabolism are reduced in SCA17. Ann Neurol (2005) 0.78
Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet (2005) 4.21
Improved clinical status, quality of life, and walking capacity in Parkinson's disease after body weight-supported high-intensity locomotor training. Arch Phys Med Rehabil (2012) 2.06
A randomized double-blind crossover trial comparing subthalamic and pallidal deep brain stimulation for dystonia. J Neurosurg (2013) 2.04
Awareness of deficits in mild cognitive impairment and Alzheimer's disease: do MCI patients have impaired insight? Dement Geriatr Cogn Disord (2004) 1.40
Motor activation in SPG4-linked hereditary spastic paraplegia. J Neurol Sci (2006) 1.37
Cognitive deficits in long-term survivors of childhood brain tumors: Identification of predictive factors. Med Pediatr Oncol (2003) 1.29
Hemodynamic and neuroendocrine responses to changes in sodium intake in compensated heart failure. Am J Physiol Regul Integr Comp Physiol (2005) 1.12
[123I]epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: implications for the use of cerebellum as a reference region. Neuroimage (2006) 1.06
Functional neuroimaging of motor control in Parkinson's disease: a meta-analysis. Hum Brain Mapp (2013) 1.03
A novel mutation in the HSPD1 gene in a patient with hereditary spastic paraplegia. J Neurol (2007) 1.02
"Central command" and insular activation during attempted foot lifting in paraplegic humans. Hum Brain Mapp (2005) 0.98
Dopa-responsive dystonia and early-onset Parkinson's disease in a patient with GTP cyclohydrolase I deficiency? Mov Disord (2006) 0.96
No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. Kidney Int (2011) 0.95
The acute brain response to levodopa heralds dyskinesias in Parkinson disease. Ann Neurol (2014) 0.93
Missense dopamine transporter mutations associate with adult parkinsonism and ADHD. J Clin Invest (2014) 0.92
Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol Psychiatry (2006) 0.92
A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. Parkinsonism Relat Disord (2009) 0.91
Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat Disord (2011) 0.91
Huntington's disease-like and ataxia syndromes: identification of a family with a de novo SCA17/TBP mutation. Parkinsonism Relat Disord (2010) 0.88
Proteomic investigations of the ventriculo-lumbar gradient in human CSF. J Neurosci Methods (2010) 0.88
Sequence variants in SPAST, SPG3A and HSPD1 in hereditary spastic paraplegia. J Neurol Sci (2009) 0.87
Semantic memory impairment in the earliest phases of Alzheimer's disease. Dement Geriatr Cogn Disord (2004) 0.84
Clinical and molecular characterization of limb-girdle muscular dystrophy due to LAMA2 mutations. Muscle Nerve (2011) 0.84
Increased urinary orosomucoid excretion is not related to impaired renal function in patients with type 2 diabetes. J Diabetes Complications (2008) 0.84
Cortical volumes and atrophy rates in FTD-3 CHMP2B mutation carriers and related non-carriers. Neuroimage (2008) 0.84
A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington's disease. Orphanet J Rare Dis (2014) 0.83
Striatal dopamine transporter binding does not correlate with clinical severity in dementia with Lewy bodies. J Nucl Med (2013) 0.83
(18)F-FDG PET/CT in a rare case of Stewart-Treves syndrome: future implications and diagnostic considerations. Lymphat Res Biol (2011) 0.82
Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med Mol Imaging (2002) 0.82
Relationship of frontal D(2/3) binding potentials to cognition: a study of antipsychotic-naive schizophrenia patients. Int J Neuropsychopharmacol (2012) 0.82
Mosaicism of the CAG repeat sequence in the Huntington disease gene in a pair of monozygotic twins. Am J Med Genet A (2004) 0.82
The lrrk2 p.Gly2019Ser mutation is uncommon in a Danish cohort with various neurodegenerative disorders. Parkinsonism Relat Disord (2011) 0.81
Performances on Symbol Digit Modalities Test, Color Trails Test, and modified Stroop test in a healthy, elderly Danish sample. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn (2012) 0.81
Reversal of pathology in CHMP2B-mediated frontotemporal dementia patient cells using RNA interference. J Gene Med (2012) 0.80
Reduced gluconeogenesis and lactate clearance in Huntington's disease. Neurobiol Dis (2010) 0.80
Showing no spot sign is a strong predictor of independent living after intracerebral haemorrhage. Cerebrovasc Dis (2014) 0.80
Reduced CSF CART in dementia with Lewy bodies. Neurosci Lett (2009) 0.80
Performances on Rey Auditory Verbal Learning Test and Rey Complex Figure Test in a healthy, elderly Danish sample--reference data and validity issues. Scand J Psychol (2011) 0.80
Behavioral variant of frontotemporal dementia mimicking Huntington's disease. Int Psychogeriatr (2010) 0.79
Reduced regional cerebral blood flow in SPG4-linked hereditary spastic paraplegia. J Neurol Sci (2005) 0.79
The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients. PLoS One (2013) 0.79
Atypical early-onset Alzheimer's disease caused by the Iranian APP mutation. J Neurol Sci (2008) 0.78
Effects of training and weight support on muscle activation in Parkinson's disease. J Electromyogr Kinesiol (2013) 0.78
The DJ-1 concentration in cerebrospinal fluid does not differentiate among Parkinsonian syndromes. Parkinsonism Relat Disord (2012) 0.78
Diagnostic profile of young and middle-aged memory clinic patients. Neurology (2002) 0.77
Prevalence and long-term clinical significance of intracranial atherosclerosis after ischaemic stroke or transient ischaemic attack: a cohort study. BMJ Open (2013) 0.77
Huntington's disease: effect of memantine on FDG-PET brain metabolism? J Neuropsychiatry Clin Neurosci (2011) 0.77
Simultaneous cardiac output and regional myocardial perfusion determination with PET and nitrogen 13 ammonia. J Nucl Cardiol (2003) 0.77
Frequency and severity of semantic deficits in a consecutive memory clinic cohort. Dement Geriatr Cogn Disord (2014) 0.76
ATXN2 with intermediate-length CAG/CAA repeats does not seem to be a risk factor in hereditary spastic paraplegia. J Neurol Sci (2012) 0.76
Germ-line CAG repeat instability causes extreme CAG repeat expansion with infantile-onset spinocerebellar ataxia type 2. Eur J Hum Genet (2012) 0.75
The authors respond. Arch Phys Med Rehabil (2013) 0.75
Familial aggregation of Parkinson's disease in the Faroe Islands. Mov Disord (2015) 0.75
Hereditary spastic paraplegia caused by the PLP1 'rumpshaker mutation'. J Neurol Neurosurg Psychiatry (2009) 0.75
[Brain--inside and outside]. Ugeskr Laeger (2002) 0.75
Alpha-contingent EEG feedback reduces SPECT rCBF variability. Int J Psychophysiol (2005) 0.75
[Dyskinesia in Parkinson's disease: an update on new neuroimaging methods and treatment possibilities]. Ugeskr Laeger (2017) 0.75
[Carriers of fragile X syndrome can present with a broad spectrum of clinical disorders]. Ugeskr Laeger (2014) 0.75
[Frontotemporal dementia]. Ugeskr Laeger (2017) 0.75
[Dementia in amyotrophic lateral sclerosis]. Ugeskr Laeger (2008) 0.75
Gamma-camera 18F-FDG PET in diagnosis and staging of patients presenting with suspected lung cancer and comparison with dedicated PET. J Nucl Med (2004) 0.75
Tremor irregularity, torque steadiness and rate of force development in Parkinson's disease. Motor Control (2012) 0.75
[Diagnostic use of SPECT with visualization of dopamine transporters in Parkinson disease. The Danish Society of Neurology]. Ugeskr Laeger (2003) 0.75
Integrated positron-emission tomography and computed tomography manifestations of cutaneous T-cell lymphoma. Arch Dermatol (2012) 0.75
[Deep brain stimulation of therapy-refractory, disabling dystonia. Danish Society of Movement Disorders (Danmodis)]. Ugeskr Laeger (2005) 0.75
[Hereditary Parkinson disease. The Danish Society of Movement Disorders]. Ugeskr Laeger (2008) 0.75
The influence of preanalytical conditions on the DJ-1 concentration in human cerebrospinal fluid. Biomark Med (2014) 0.75